Elenestinib

Elenestinib (BLU-263) is a small-molecule drug developed by Blueprint Medicines. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04910685 ((HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis), in systemic mastocytosis. The largest, NCT04910685, plans to enrol 534 participants with primary completion expected 2032-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.